Mesothelioma Community Will Convene to Focus on Cure ...

...Mesothelioma Community Will Convene to Focus on Cure - International Research Symposium Unites Patients, Advocates, Foremost Medical Experts: Financial News - Yahoo!

Finance Yahoo!

My Yahoo!

Mail Welcome, Guest [Sign Out, My Account] Finance Home - Help Welcome [Sign In] To track stocks & more, Register Financial NewsEnter symbol(s) BasicPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup Press ReleaseSource: Mesothelioma Applied Research Foundation Mesothelioma Community Will Convene to Focus on Cure - International Research Symposium Unites Patients, Advocates, Foremost Medical ExpertsThursday September 22, 5:00 am ET SANTA BARBARA, Calif., Sept.

22 /PRNewswire/ - The urgent mission to improve treatments for a deadly, asbestos-related cancer will make another step forward, the Mesothelioma Applied Research Foundation (MARF) announced today, with the Second International Symposium on Malignant Mesothelioma.

Meso is a malignant tumor that aggressively invades the linings of the lungs, abdomen, heart or testicles.

The need for research to develop effective treatments was neglected for decades.

But in the past few years, exciting progress has begun.

MARF, the national nonprofit whose mission is to eradicate meso as a life-ending disease, has organized the Symposium to review this progress, elucidate the latest advances, and strengthen and encourage the entire meso community.The Symposium will be held in Las Vegas at the Caesars Palace conve...

Combination of Alimta® and Gemzar® Does Not Improve Pancreatic ...

... Combination of

OSI / Genentech / Roche: Tarceva triumphs again

... OSI / Genentech / Roche: Tarceva triumphs again - Pharmaceutical Business Review SEARCH THIS SITE IN All Of The Site News & Features Research Company Intelligence Go You are here: Home Article Home Sign up for free newsletters Features News Research Company Intelligence Research Store Browse By Industry Recent Research Best Sellers Industry Profiles Customer Service Company Intelligence Find A Company About This Site About This Site Advertise with us Contact us Add site to favorites Privacy policy For Your Site (XML) RSS Feed - Features RSS Feed - Companies OSI / Genentech / Roche: Tarceva triumphs again A study has revealed that Tarceva benefits elderly lung cancer patients.

19 Sep 2005, 17:16 GMT - The results of a phase II study have suggested that OSI Pharmaceuticals, Genentech and Roche's Tarceva may be particularly beneficial in elderly patients with previously untreated lung cancer.

These results may increase off-label first-line use of the drug in such patients, although Tarceva's high price may hinder uptake in this setting.

The results of the phase II trial demonstrated that Tarceva (erlotinib) has activity as a first-line therapy in elderly (over 70 years) non-small cell lung cancer (NSCLC) patients.

In the study, a total of 80 patients were treated with single-agent Tarceva between 2003 and 2005, and 69 patients were evaluated for best response.

Although no patients demonstrated a compl...

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | All news